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 Spinal Muscular Atrophy (SMA) is an autosomal recessive disease that causes a 
degeneration of the anterior horn cells of the spinal cord. SMA Type I is the most severe 
form, characterized by progressive muscle weakness and atrophy. SMA Type I patients 
are susceptible to nutritional deficiencies, especially those that correlate to bone health, 
due to decreased caloric intake and limited weight bearing.  
The aim of this study was to evaluate and assess: 1) the adequacy of vitamin D 
intake as compared to the American Academy of Pediatrics recommendation of 400 
IU/day; 2) the correlation between vitamin D intake and associated serum level; and       
3) the association between vitamin D and calcium intakes and bone mineral density.  
All subjects are participants in an ongoing natural history study at the University 
of Utah. Participants have a genetic diagnosis of SMA and a clinical diagnosis of Type I. 
Vitamin D and calcium intakes were assessed with a 3-day food record. Vitamin D serum 
levels were evaluated from 25-hydroxy vitamin D lab testing. Bone mineral density 
(BMD) was assessed using Dual Energy X-ray Absorptiometry Scan (DEXA) of the 
subjects’ whole body.  
Subjects (n=40) consisted of 22 males and 18 females. The mean age of the 
subjects was 18.6 months (range 0 to 165 months). Seventy-five percent of patients had 
an inadequate intake of vitamin D at the initial visit. Vitamin D intake and calcium intake 
were positively correlated with BMD (r=0.31 and r=0.53, respectively). Increased 
vitamin D and calcium consumption were associated with an increase in BMD (p=0.04 
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and p=0.01, respectively). Vitamin D intake correlated positively with serum levels of 
vitamin D (r=0.65). Within a subset of 14 patients, 71% had a serum vitamin D level in 
the optimal range.  
The majority of patients (75%) reported an inadequate vitamin D intake at their 
first visit (<400 IU). Inadequate nutrient intake is likely due to the decreased caloric 
needs of SMA Type I patients. Decreased intake of vitamin D and calcium were 
associated with a decreased BMD which increases the risk of fractures, scoliosis, and 
osteoporosis. There continues to be a need for evidence-based research concerning the 
nutritional needs of SMA Type I patients. Future research involving an experimental 
study is necessary to determine optimal intakes of vitamin D and calcium in the SMA 
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 Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized 
by a mutation in the survival motor neuron 1 (SMN1) gene. A corresponding deficiency 
of the survival motor neuron (SMN) protein causes a degeneration of anterior horn cells 
in the spinal cord, which leads to progressive muscle atrophy and weakness (1). Severity 
of the disease is determined by the amount of the SMN2 gene (1). 
 The most severe form of SMA, Type I, is the leading genetic cause of infant death 
with an incidence of 1 in 10,000 live births (2). Types of SMA are categorized by age of 
onset and motor-function achieved (1, 3). Type I, also known as Werdnig-Hoffmann 
disease, is the most common form of SMA; it is diagnosed before 6 months of age, and 
30% of cases are diagnosed prenatally. This form of the disease is rapidly progressive, 
with a poor prognosis. More recently, due to proactive care, life expectancy may extend 
past the age of 2 years. In these patients, motor function is impeded by severe hypotonia. 
For example, affected children are unable to sit unassisted and lack head control (1, 3, 4).  
 Muscle weakness causes a multitude of problems in the orthopedic, pulmonary, 
and gastrointestinal systems. Children with SMA are at risk for osteoporosis, fractures, 
and scoliosis. Restrictive lung disease, due to decreased pulmonary function, is the most 
common and life-threatening complication specifically in Type I patients (5). Dysphagia, 
gastrointestinal dysmotility, and constipation are complications associated with muscle 
weakness in the gastrointestinal system (5). Type I patients commonly experience 
problems with bulbar denervation, resulting in dysphagia and fatigue, thus increasing the  
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risk of the patient becoming failure to thrive (FTT). This is a dangerous cycle as feeding 
problems and constipation increase the risk of poor intake and FTT, which can lead to 
further weakness and continued feeding problems. Enteral feeds may be required for 
patients with dysphagia. While FTT is a problem for a proportion of this population, 
obesity is as well. SMA Type I patients have a lower metabolic rate, due to decreased 
lean body mass; therefore, excessive weight gain is a concern. Appropriate calories and 
adequate nutrient intake must be considered when assessing the nutritional needs of a 
patient with SMA.  
 Nutritional management is directed toward providing nutritional requirements and 
improving the quality of life for Type I patients. Although nutrition plays a major role 
throughout the progression of SMA, there is little research to make a conclusive 
recommendation for specific nutrient supplementation. The decreased amount of lean 
body mass and limited activity of SMA Type I patients may translate to a reduced 
metabolic rate. The daily caloric intake of this population is significantly less than the 
recommendation for healthy children their age (6). Dietary management requires a 
balance of calories and nutrients to prevent excess weight gain and undernutrition. 
Catabolism due to illness, surgery, and undernutrition can be catastrophic in the SMA 
population as any muscle regression can be permanent. The use of parenteral or enteral 
nutrition is common when prolonged fasting is anticipated (7).  
 Although SMA patients have different caloric needs, micronutrient requirements 
are currently considered to be the same as their age-matched peers. A reduced caloric 
intake can lead to inadequate micronutrient consumption. SMA Type I patients are 
particularly susceptible to vitamin D deficiencies, not only because of poor intake, but 
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also because of decreased movement and drug-nutrient interactions. For example, 
valproic acid/carnitine, sodium phenylbutyrate, and hydroxyurea are common drug 
therapies used to treat symptoms of neurological diseases including SMA. These types of 
treatments can interfere with the absorption of certain micronutrients such as vitamin D 
(8).  SMA children are at greater risk for osteoporosis, fractures and scoliosis; therefore, 
close monitoring of micronutrients associated with bone health is essential (6, 7, 9). 
Specifically, a biochemical evaluation of vitamin D status is a key consideration to 
confirm a deficiency in at-risk patients. 
 The purpose of this study was to assess the vitamin D intake of a SMA Type I 
population, as compared to the recommendation from the American Academy of 
Pediatrics (AAP), 400 IU/day (10). We also evaluated the dietary intake of vitamin D 
compared to corresponding serum levels and bone mineral density (BMD).  We 
hypothesized that: 1) vitamin D intake of SMA Type I patients is lower than the level 
suggested by the AAP for children of the same age as a result of a reduced calorie diet; 2) 
a vitamin D intake lower than the recommendation is associated with a serum level below 
the ideal range; 3) a suboptimal vitamin D intake is associated with poor bone health 
indicators. The hypotheses were tested with a 3-day food record, a serum vitamin D test, 








 This was an observational study of vitamin D intake in Spinal Muscular Atrophy 
Type I patients. All subjects represented a convenience sample of participants in a natural 
history study conducted by the Pediatric Motor Disorders Research group at the 
University of Utah.  
 
Subject Selection Criteria 
 Potential subjects were participants in an ongoing clinical outcomes trial for SMA 
Type 1. Inclusion criteria consisted of a clinical diagnosis of Type 1 and a genetic 
diagnosis of SMA. The mean age of subjects was 18.6 months with a median of 10 
months. Participants ranged between 0 months to 165 months in age. Subjects were 
recruited between June 1, 2001 and February 1, 2011. Written informed parental 
permission (subjects <18 years) and assent (subjects >7 years) were obtained for all 
subjects. This study protocol was approved by the Institutional Review Board at the 
University of Utah. 
 




 At study initiation, parents were asked to complete a 3-day food record for their 
child. Three-day food records were filled out for each clinic visit. Parents were given a 
packet explaining how to fill out a record of dietary, fluid, and supplement intake for two  
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weekdays and one weekend day. For a sample dietary intake form as it appears on the 
SMA website, see Appendix. The growth parameters of body weight, length, and age 
were assessed either in a clinic or at home; this information was included with each diet 
record submission. A food record was submitted by parents in one of three ways: 
bringing a hand written copy to their clinical visit; entering an online version on the SMA 
and Nutrition website; or faxing/emailing a copy to the Pediatric Motor Disorders 
Research group.  
The 3-day dietary records were analyzed using ESHA Food Processor (versions 
9.1.0 and 10.5.2, ESHA Research, Salem, Oregon) for vitamin D and calcium intake. 
Vitamin D intake less than 400 IU/day was considered to be deficient; between 400 and 
2000 IU was optimal; and greater than 2000 IU was considered a possible toxicity.  
Vitamin D and calcium intake values were compared to BMD. 
From 2009 to present, a dietitian reviewed each dietary analysis and provided 
feedback to parents. Primarily, the type of diet and formula was chosen by the parent 
and/or primary care provider. The aim of this study was to evaluate the diet from the 
initial visit against our outcome variables. Food records were collected for the initial visit 
from all subjects (n=40). Three-day food records were also collected from patients at 




A subgroup of subjects had a blood test for serum 25-OH D3 and serum calcium 
levels. Subject vitamin D levels were stratified into the following categories: less than 20 
ng/mL (deficient), between 20 and 29.9 ng/mL (inadequate), between 30-39.9 ng/mL 
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(low normal), 40-80 ng/mL (optimal), and greater than 80 ng/mL (high). In addition, 
vitamin D serum levels were compared to corresponding dietary intake.  
 
Duel-Energy X-ray Absorptiometry Scan 
 A subgroup of 37 subjects underwent a DEXA scan at each visit to evaluate bone 
mineral density and bone mineral content. Norland DEXA (XR-36 software version 3.3.1 
Fort Atkinson, Wisconsin) for small subjects was used. DEXA has been validated as an 
appropriate measure of bone mineral density in the target population (12, 13).    
 
Demographic Data 
 Parents provided demographic data on the parental consent form. Gender and 
ethnicity were reported for all patients (n=40) and their parents. In addition, the age of the 
patient was collected on the parental consent form.   
 
Medical History Variables 
 Parents were asked to report the patient’s medical history on the parental consent 
form. Types of data included family medical history, presence of allergies, medication 
use, lab results, and physical exam information. 
 
Statistical Methods, Data Analysis, and Interpretation 
The Statistical Analysis Software (version 9.1.2, 2010, SAS Institute Inc., Cary, 
NC, USA) was used to conduct data analyses. A power analysis for the study dependent 
variable, vitamin D intake, revealed that a sample size of 14 subjects was required to 
detect a 10% difference from the population mean represented as the AAP 
recommendation. Vitamin D intake and serum levels were stratified into categories and 
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the associations were analyzed with Pearson’s correlation. The correlation between 
vitamin D intake and follow-up visits was conducted with regression analysis. Mixed-
effects analysis was employed to compare vitamin D intake to BMD and calcium intake 
to BMD (14). The association between vitamin D and calcium intake and bone health 
measures was assessed for all participants (n=40). For all analyses, the level of 




 Demographic data for the study population are presented in Table 1. Subjects 
(n=40) consisted of 22 males (55%) and 18 females (45%). Patients ranged in age 
between 0 and 165 months. The median age was 18.6 months and the mean age was 10.0 
months. The subject population age was slightly skewed to the right due to a patient who 
was 165 months at the time of visit. Inclusion of this outlier in the analysis did not 
significantly affect the results. The majority of patients classified themselves as White, 
Non-Hispanic. Data were collected for 98 visits, of those, there were 40 initial 3-day diet 
records, 14 25-OH D3 tests, 80 total body bone mineral density DEXA scans, and 63 
serum calcium levels. There were data from follow-up visits for 24 patients. The age of 
patients at follow-up visits ranged from 3.38 to 81.47 months (mean 23.49 months).  
 Three-day food diet records were analyzed for vitamin D and calcium intakes. 
Vitamin D intake from the initial visit was compared to the recommended value from the 
AAP (400 IU). Seventy-five percent of patients had an inadequate vitamin D intake at the 
first visit. Baseline vitamin D intake data for 40 initial visits are presented in Table 2. 
Vitamin D intake was plotted over 3 years for those patients with follow-up visits. There 
was not a clear pattern of vitamin D intake over time between patients. Vitamin D intake 














Male 55.0 (n=22) 
Female 45.0 (n=18) 
Ethnicity (%) 
White/Non-Hispanic 90.0 (n=36) 









Table 2. Vitamin D Intake at Baseline 










a <400 IU/day    b 400-2000 IU/day    c >2000 IU/day 
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Fourteen subjects had a serum 25-OH D3 level taken during the same visit that a 
diet record was available. For this subgroup, only one subject had an inadequate serum 
level (<29.9 ng/mL). Seventy-one percent of patients in the subgroup (n=10) had a serum 
vitamin D level within the optimal or high range (> 40 ng/mL). The rest were in the low 
normal range. A higher vitamin D intake was associated with an elevated serum level. 
However, when these two sets of values were stratified into categories, the two measures 
did not correlate (Figure 1). Half of the patients with optimal serum levels had an 
inadequate intake, and twenty nine percent of patients consuming an optimal intake had a 
serum level that was classified as high.  
 The result of each DEXA scan was compared with a vitamin D intake and a 
calcium intake from the same visit. Data from 80 visits were analyzed for vitamin D 
intake and 76 visits for calcium intake. The correlation between vitamin D intake and 
bone mineral density was significant (r=0.31 p=0.04). The same was true for calcium 
intake and bone mineral density (r=0.53 p=0.01) (Figures 2 and 3).  
 There were only five serum vitamin D levels that corresponded with a bone 
mineral density value; therefore, the sample size was too small to conduct a reliable 
analysis. Calcium serum levels were too tightly ranged (9-10.7mg/dL), with limited 
variation, to show a correlation with bone mineral density.   
    


























Figure 3. Correlation between calcium intake (mg) and bone mineral density (g/cm
2
) 







Overall, the results from this observational study supported the hypothesis that 
SMA Type I patients are at risk for nutrient deficiencies. SMA Type I patients have a 
lower metabolic rate due to decreased lean muscle mass and limited movement (6). 
Therefore, for this type of SMA, patients require fewer calories per day than their healthy 
age-matched peers (6). With decreased caloric intake, achieving adequate micronutrient 
intake can be difficult. The majority of patients in this study (75%) had inadequate 
intakes of vitamin D at baseline. Despite receiving food record analysis feedback, 
improvement in vitamin D intake was only slightly correlated with time (r=0.23 
p=0.0021). Some patients increased their vitamin D intake in the 3 years following their 
initial visit; others decreased or maintained their intake of vitamin D. Barriers to 
obtaining an adequate amount of vitamin D also included: lack of sun exposure due to 
geographic location, limited time outside, or increased use of sunscreen (15). Another 
barrier specific to the SMA population is the use of anticonvulsant drugs such as valproic 
acid/carnitine, sodium phenylbuterate, and hydroxyurea, which can interfere with the 
absorption of vitamin D (8).  
A serum vitamin D test was collected from a subset of patients (n=14). There was 
only one patient with multiple serum levels. In this case, only the initial level was used 
for analysis.  Serum vitamin D levels and vitamin D intake were strongly correlated 
(r=0.65). However, when serum and intake levels were stratified into categories, the two 
measures did not correlate. This lack of significance  was  likely  due  to  a  small  sample  
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size. For example, six patients within the subset had inadequate intake, 50% (n=3) had 
optimal blood levels.  
The majority of serum levels (71%, n=10) were optimal or high (>40 ng/mL). A 
possible explanation for this result is that biological vitamin D levels were not tested until 
later in the study when there was greater media coverage of the health benefits of vitamin 
D (16). The first serum test was conducted in 2007, 6 years after data collection began. 
Clinicians and parents may have had better awareness of the role of the vitamin and the 
incidence of deficiency and, therefore, were more likely to supplement. Another 
explanation for the majority of serum levels falling in the optimal-high range is season. In 
a vitamin D study, winter was one factor of low vitamin D status in children 5-14 years 
old (17). Seventy-one percent (n=10) of blood tests were drawn between April and 
October, which represents a time of potentially greater sun exposure for study 
participants. 
   Calcium and vitamin D intakes from 80 visits were individually compared to 
corresponding BMD scores. DEXA scans and food records were matched as closely as 
possible by date. Most DEXA scans and food records were recorded at the same visit. In 
three instances a DEXA scan was not conducted at the same visit that a food record was 
received. BMD is a long-term measure of calcium and vitamin D intake. Therefore, we 
assumed that a DEXA scan would reflect micronutrient intake. 
A stronger correlation exists between calcium intake and BMD (r=0.53, p=0.1) 
than vitamin D intake and BMD (r=0.31, p=0.4). This result was expected because 
calcium has a direct effect on bone mineralization, while vitamin D has an indirect effect 
(15). As expected, improvements in vitamin D and calcium intake were associated with 
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an increase in BMD. The same results were reflected in studies conducted with healthy 
individuals (18, 19, 20). Attenuating BMD increases the risk of fracture, scoliosis, and 
osteoporosis. A reference value has not been established for this age range and 
population; therefore, a statistical analysis of BMD compared to normal values was not 
conducted. 
Serum calcium is not a good measure of calcium status because the body is very 
efficient in regulating levels to a tight range. Serum calcium does not reflect calcium 
intake or bone health (15). This statement was evidenced by the limited variance 
observed in serum calcium levels (9-10.7mg/dL). For this reason, statistical analysis was 
not performed to compare serum calcium and BMD or calcium intake. 
The sample of vitamin D serum levels was too small to make a reliable 
comparison to BMD. We chose to include this subset of patients to observe preliminary 
vitamin D status in this population.  In future studies, obtaining a 25-OH D3 level for each 
subject would be beneficial for determining if vitamin D intake is optimal. BMD is one 
functional measure of vitamin D intake, although the test is neither specific nor sensitive. 
Other studies have established a relationship between 25-hydroxy serum levels and BMD 
of adolescent women (18, 21). Vitamin D serum levels are reflective of vitamin D intake 
as the majority of biological vitamin D is pooled in the blood (15).   
 A strength of this study is the methodology for data collection. A 3-day dietary 
record is a validated measure for assessing intake, particularly for this population (11). 
SMA Type I patients require 24-hour care, consequently a parent or caregiver can record 
intake for the child at regular intervals throughout the day; this is likely to increase 
accuracy. More recently an evaluation of the food record by a registered dietitian who 
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specializes in SMA provides an incentive to parents who are likely motivated to find the 
best dietary management for their children. A blood test is an accurate method of 
assessing dietary intake of vitamin D (15). The test is used exclusively in clinical settings 
to measure the adequacy of a patient diet for vitamin D. A DEXA scan is used clinically 
to diagnose poor bone mineral density; the scan is the most valid and reliable measure 
available (12, 13).  
 This was an observational design; therefore, the study lacked power compared to 
an experimental study. The objective of this study was not to impose a dietary 
intervention, but rather to observe current dietary practices among the SMA population. 
Another limitation of this study was the lack of vitamin D serum data for all participants 
with a food record. We chose to include a subset of subjects who did receive a blood test, 
because this measure is a practical application for assessing vitamin D adequacy in the 





Nutrition plays a vital role in the quality of life and outcome of spinal muscular 
atrophy (2, 22). Despite this role, there is very little evidence-based research to support a 
recommendation for dietary management in this population. In fact, most SMA patients 
do not have access to a registered dietitian, much less one who specializes in SMA. 
Parents and caregivers are responsible for choosing a diet for the patient themselves (22).  
This study aimed to observe dietary practices of SMA Type I children. The results 
supported the hypothesis that Type I patients are at risk for nutrient deficiencies due to 
decreased caloric intake (6). However, inadequate intakes of vitamin D were not reflected 
in corresponding serum levels in our small subset of patients. When making a 
recommendation for this population, caloric and micronutrient intake are equally 
important. Nutrient supplementation may be necessary if appropriate nutrient intake 
cannot be met while adhering to restricted calories. Further prospective studies will be 
necessary to determine optimal intakes of vitamin D and calcium in the SMA Type I 
population.!
 APPENDIX 
THREE-DAY FOOD RECORD 
 
 
Subject Unique ID (Not Study ID)  
Subject’s Name  
Person Filling Out Form  
Relationship to Patient  
Height Feet  
Height Inches  
Height Cm  
Weight Pounds   
Weight Oz  
Weight Kg  
Child’s current feeds  
Child’s Age                    years              months 
 
 Name Amount 
Special Formula Ingredients 
Special Formula Ingredient  1  
Supplements 
Additional Supplement  1  
1  Food Record Day 1 
Date: 2  
1  Food Record Day 2 
Date: 2  
1  Food Record Day 3 
Date:  2  
 
Breast Feeding   
Day 1  Date:  
Day 1 Pre Weight                        kg  
                        lbs                      oz 
Day 1 Post Weight                        kg  
                        lbs                      oz 
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